Brain Tumour Treatment Now Available in Canada, First to Deliver Chemo Directly to the Affected Site
Gliadel® Wafer approved by Health Canada for patients with Glioblastoma Multiforme
MISSISSAUGA, ON, - Eisai Limited, a wholly-owned Canadian subsidiary of Eisai Inc., announced today the Health Canada approval and availability of Gliadel® Wafer (carmustine implant in polifeprosan 20) indicated in recurrent Glioblastoma Multiforme (GBM) patients for whom surgical resection is indicated as an adjunct to surgery.
Read Full Article...
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy